Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by ARCH Venture Partners XII, LLC. Officer active across 4 companies, notably Neumora Therapeutics, Inc.. Cumulatively, 16 filings have been published. Split: 11 buys · 0 sell. Total volume traded: €34.8m. History available since 22 September 2023. The latest transaction was disclosed on 27 October 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to ARCH Venture Partners XII, LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
40,000 shares@ US$11.1441.6% of flowCommon StockSEC:0001062993-23-018469:0
Canonical exit: 21 Dec 2023 (T+90)
16 of 16 declarations
About ARCH Venture Partners XII, LLC
ARCH Venture Partners XII, LLC has filed 16 filings in total. Across the 16 recent filings available, all transactions are acquisitions, with buy volume of EUR 34763745 between 2023-09-25 and 2025-11-14. The companies involved are Neumora Therapeutics, Inc., Metsera, Inc., where the entity is a Director, Prime Medicine, Inc., and Rapport Therapeutics, Inc.